Español
Questions About Cancer? 1-800-4-CANCER
  • Email

Clinical Trials Search Results

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 152 for your search:
Drug:  sorafenib tosylate
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Natural history/Epidemiology
Status: Approved-not yet active
Age: Any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: 15246, NX0913IN, NCT01353794

2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 2011PTAHCC, NCT01409499

3.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: TACE-Sorafenib, NCT01833299

4.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12-213, NCT01849588

5.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: INT 80/09, NCT01387503

6.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: OP2, NCT01747642

7.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: XHDD-001, NCT01906216

8.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: QCH20130823, NCT01932385

9.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: HCC201408, NCT02220088

10.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11718, UVACC-ONYX-11718, UVACC-HIC-11860, EUDRACT-2005-0000941-12, BAYER-UVACC-ONYX-11718, NCT00111007

11.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000564099, IPC-BAYPAN, INCA-RECF0426, IPC-2005-006, BAYPAN, NCT00541021

12.

Phase: Phase III
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12311, 2007-002604-17, NCT00625378

13.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01989, CDR0000659348, CALGB 80802, U10CA180821, U10CA031946, NCT01015833

14.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AHCC06, NCT01135056

15.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: SILIUS Phase III trial, NCT01214343

16.

Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Esperanz-002, NCT01265810

17.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Under 30
Sponsor: NCI
Protocol IDs: NCI-2011-02670, COG-AAML1031, CDR0000701850, AAML1031, U10CA098543, U10CA180886, NCT01371981

18.

Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: BOOST, EudraCT number 2009-013870-42, NCT01405573

19.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P101103, NCT01482442

20.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TS-103, NCT01556490

21.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 16037 / AN 33/11, 2011-004396-36, NCT01613846

22.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG 1112, NCI-2012-02057, U10CA021661, NCT01730937

23.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: E7080-G000-304, NCT01761266

24.

Phase: Phase III
Type: Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: STAH Korea Trial, NCT01829035

25.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TS-104, 2012-005375-14, NCT01887717
1     
New Search